Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
OpenAI Restricts Astra AI Over Cyberattack Risks 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
S&P 500, Nasdaq Futures Rise as Iran Risks and CPI Loom 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Mizuho has unveiled its January US Top Picks, spotlighting Chewy, GE Vernova, Enliven Therapeutics, Quest Diagnostics, DuPont, and Salesforce. These companies align with Mizuho’s high-conviction investment ideas, driven by expected catalysts over the next year.
Chewy earned a spot for its strong EBITDA margin expansion, supported by automation, vet-focused initiatives, and app engagement. With a $42 price target, analysts see a 17% upside for the pet retailer.
GE Vernova stands out as a key player in power generation, providing turbines and grid equipment that supply 30% of global electricity. Mizuho forecasts significant growth in natural gas power contracts by 2025, driven by rising data center demand.
Enliven Therapeutics shows promise with ELVN-001, an investigational tyrosine kinase inhibitor (TKI) demonstrating early efficacy in chronic myeloid leukemia (CML). Analysts see potential for ELVN-001 to expand into first-line treatment, bolstering its market outlook.
Quest Diagnostics appeals for its stable cash flow and growth opportunities in diagnostics, underpinned by Medicare and commercial pricing strength. Mizuho highlights its acquisition pipeline and EPS growth forecast for 2025.
DuPont’s planned split into ElectronicsCo, WaterCo, and the new DuPont is seen as a value catalyst. Analysts cite the company’s leadership in specialty materials like Kevlar and Tyvek, alongside seasonal sales recovery and electronics growth.
Salesforce rounds out the list, with Data Cloud and Agentforce technology driving productivity and revenue growth. Upcoming updates, multi-cloud deals, and margin improvements position Salesforce for continued success in digital transformation.
These additions reflect Mizuho’s strategic outlook for 2024, showcasing diverse opportunities across industries.
